Non-beta-lactam GLT-1 activators: characterization in preclinical models of opioid and cocaine addiction
非 β-内酰胺 GLT-1 激活剂:阿片类药物和可卡因成瘾临床前模型的表征
基本信息
- 批准号:10265449
- 负责人:
- 金额:$ 41.76万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-09-30 至 2025-06-30
- 项目状态:未结题
- 来源:
- 关键词:Active Biological TransportAddressAdverse effectsAffectAgonistAnimal ModelAntibiotic ResistanceAstrocytesBehavioralBiological AssayBiological MarkersBrainBrain IschemiaCentral Nervous System DiseasesCerebellar AtaxiaChemistryChronicClinicClinical TrialsCocaineCocaine AbuseCocaine DependenceCuesDataDevelopmentDiarrheaDoseDrug AddictionDrug KineticsDrug abuseEnhancersEnzymesFemaleFoodGLAST ProteinGenerationsGlutamate TransporterGlutamatesIn VitroIntakeIntestinal AbsorptionInvestigationLaboratoriesLinkLiverMetabolicMetabolismMethadoneModelingMonobactamsMorphineMotor ActivityNaloxoneNeurological ModelsNeuronsNucleus AccumbensObsessive-Compulsive DisorderOpiate AddictionOpioidOralOutcomeOxycodonePalateParentsPatientsPharmaceutical PreparationsPharmacodynamicsPharmacologic SubstancePharmacologyPharmacotherapyPhase I Clinical TrialsPhysical DependencePlasmaPre-Clinical ModelProdrugsProteinsPsychological reinforcementRattusRelapseReplacement TherapyRewardsRiluzoleSafetyScheduleSelf AdministrationSolubilitySpinalStructureSucroseSystemTestingTranslationsUp-RegulationWithdrawaladdictionanalogaqueousbasebeta-Lactamsbuprenorphine abuseclinical translationcocaine exposurecocaine relapseconditioned place preferencedependence relapsedesigndruggable targeteffective therapyeffectiveness testingextracellulargastrointestinal systemhealthy volunteerimprovedin vivoin vivo evaluationinterestliver metabolismmalenervous system disorderneurochemistryopioid exposurepainful neuropathyparenteral administrationpharmacokinetics and pharmacodynamicspre-clinicalpreclinical studypreferenceprescription opioidprotein expressionreuptaketherapeutic targettransmission processuptake
项目摘要
PROJECT SUMMARY
No approved medications are available for cocaine abuse, and medications for opioid addiction are limited to
agonist replacement therapies that are abuse liable themselves. Glutamate is one neurochemical system that
has been recently for drug dependence and relapse. One of the most viable therapeutic targets within the
glutamate system is glutamate transporter subtype 1 (GLT-1), a predominantly astrocytic protein that clears
glutamate from the extracellular compartment in the CNS. GLT-1 transport and uptake mechanisms are
dysregulated during COC or opioid exposure and facilitate the enhanced glutamate transmission in brain
reward circuits that underlie dependence and relapse. Agents that enhance the expression of GLT-1
transporters do display efficacy in preclinical models of drug addiction and related CNS disorders, but an
existing hurdle is the disappointing clinical translation. Part of the problem is the agents themselves, which are
limited mostly to β-lactam antibiotics that suffer from a host of pharmacokinetic and pharmacodynamic issues,
including parenteral administration, poor brain penetrability, chronic dosing, adverse effects, and a slow onset
of CNS efficacy that is dependent on increased GLT-1 protein expression. In this proposal, we address both
the lack of effective treatments for cocaine and opioid addiction and the limited diversity in the GLT-1 activator
pipeline. We propose to characterize the efficacy of two non-β-lactam GLT-1 activators (e.g. troriluzole [TRLZ]
and NA-014) in rat assays that model cocaine and opioid reinforcement, dependence, and relapse. TRLZ is a
prodrug of riluzole (approved for ALS) that is already being tested in clinical trials for obsessive-compulsive
disorder and spinal cerebella. TRLZ displays a unique pharmacodynamic profile in that it acts that acts through
a dual mechanism to enhance cellular glutamate uptake and inhibit neuronal glutamate release. Despite a
glutamate-based profile that is favorable for potentially treating drug abuse, the parent drug RLZ has only been
assessed in few preclinical studies that have yielded mixed outcomes. Our interest in RLZ-like compounds for
drug addiction was recently reignited by a 2018 study showing that RLZ reduces cocaine relapse in rats. RLZ
itself, however, is an unlikely candidate for repurposing because of reduced efficacy and potency related to
pharmacokinetic limitations, including high first-pass hepatic metabolism, elevated liver enzymes, a negative
food effect, low aqueous solubility, and poor oral palatability. To mitigate limitations of RLZ, we designed,
synthesized, and evaluated TRLZ as a third-generation prodrug with optimized in vitro and in vivo features.
The second GLT-1 activator is NA-014, which directly activates GLT-1 through selective allosteric modulation
of GLT-1 after a single exposure, making it different from β-lactams that rely on upregulation of the GLT-1 but
only after repeated treatment with high doses. In summary, our results will offer the first comprehensive
information about the efficacy of non-β-lactam GLT-1 activators in preclinical models of drug addiction, and, if
positive, may pave the way for the development of safer and more effective GLT-1-based medications.
项目总结
目前还没有批准的可卡因滥用药物,治疗阿片成瘾的药物仅限于
滥用的激动剂替代疗法本身就有责任。谷氨酸是一种神经化学系统,
最近因药物依赖和复发而被捕。最可行的治疗靶点之一
谷氨酸系统是谷氨酸转运体亚型1(GLT-1),是一种主要的星形细胞蛋白,可以清除
谷氨酸来自中枢神经系统的胞外隔室。GLT-1的转运和摄取机制是
在COC或阿片类药物暴露过程中调节失调,促进谷氨酸在脑内的增强传递
依赖和复发背后的奖赏回路。促进GLT-1表达的药物
转运蛋白在药物成瘾的临床前模型和相关的中枢神经系统疾病中确实显示出疗效,但
现存的障碍是令人失望的临床翻译。问题的一部分是代理本身,它们是
主要限于β-内酰胺类抗生素,这些抗生素存在一系列药代动力学和药效学问题,
包括肠外给药、脑渗透性差、慢性给药、不良反应和起病缓慢。
中枢神经系统的疗效依赖于GLT-1蛋白表达的增加。在这项提案中,我们解决了这两个问题
缺乏治疗可卡因和阿片成瘾的有效方法,以及GLT-1激活剂的多样性有限
输油管道。我们建议对两种非β-内酰胺类GLT-1激动剂(例如曲利鲁唑)的疗效进行表征
和NA-014)在大鼠实验中模拟可卡因和阿片类药物的强化、依赖和复发。TRLZ是一种
利鲁唑前药(批准用于ALS),已在强迫症的临床试验中进行测试
精神障碍和小脑脊髓炎。TRLZ显示了独特的药效学特征,因为它通过
促进细胞谷氨酸摄取和抑制神经元谷氨酸释放的双重机制。尽管有一个
基于谷氨酸的特征有利于潜在地治疗药物滥用,母药RLZ只有
在少数临床前研究中进行了评估,结果喜忧参半。我们对RLZ类化合物的兴趣
最近,2018年的一项研究表明,RLZ减少了大鼠的可卡因复发,重新点燃了毒瘾。RLZ
然而,它本身不太可能被重新利用,因为与以下相关的效力和效力降低了
药代动力学限制,包括高首过肝代谢率,肝酶升高,阴性
食物效果差,水溶度低,口感差。为了减轻RLZ的限制,我们设计了
合成并评价了体内外优化的第三代前药TRLZ。
第二个GLT-1激活剂是NA-014,它通过选择性变构调节直接激活GLT-1
不同于依赖于GLT-1上调的β-内酰胺类药物,但
只有在反复使用高剂量治疗后才会发生。总而言之,我们的成果将提供第一个全面的
关于非β-内酰胺类GLT-1激动剂在药物成瘾的临床前模型中的有效性的信息,以及,如果
阳性,可能为开发更安全和更有效的基于GLT-1的药物铺平道路。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
SCOTT M. RAWLS其他文献
SCOTT M. RAWLS的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('SCOTT M. RAWLS', 18)}}的其他基金
Kratom and Cannabinoid Constituents: Mechanisms and Interactive Effects in Neuropathic Pain
卡痛和大麻素成分:神经性疼痛的机制和相互作用
- 批准号:
10745835 - 财政年份:2023
- 资助金额:
$ 41.76万 - 项目类别:
Non-beta-lactam GLT-1 activators: characterization in preclinical models of opioid and cocaine addiction
非 β-内酰胺 GLT-1 激活剂:阿片类药物和可卡因成瘾临床前模型的表征
- 批准号:
10417232 - 财政年份:2020
- 资助金额:
$ 41.76万 - 项目类别:
Non-beta-lactam GLT-1 activators: characterization in preclinical models of opioid and cocaine addiction
非 β-内酰胺 GLT-1 激活剂:阿片类药物和可卡因成瘾临床前模型的表征
- 批准号:
10652316 - 财政年份:2020
- 资助金额:
$ 41.76万 - 项目类别:
Therapeutic secrets of kratom alkaloid mitragynine: Testing efficacy in preclinical neuropathic pain and abuse liability models and characterization of underlying opioid and adrenergic mechanisms
卡痛生物碱帽柱木碱的治疗秘密:测试临床前神经性疼痛和滥用倾向模型的功效以及潜在阿片类药物和肾上腺素能机制的表征
- 批准号:
9910367 - 财政年份:2019
- 资助金额:
$ 41.76万 - 项目类别:
Chemokine CXCL12/CXCR4 system and synthetic cathinones
趋化因子CXCL12/CXCR4系统和合成卡西酮
- 批准号:
10187189 - 财政年份:2018
- 资助金额:
$ 41.76万 - 项目类别:
Chemokine CXCL12/CXCR4 system and synthetic cathinones
趋化因子CXCL12/CXCR4系统和合成卡西酮
- 批准号:
9913484 - 财政年份:2018
- 资助金额:
$ 41.76万 - 项目类别:
Chemokine CXCL12/CXCR4 system and synthetic cathinones
趋化因子CXCL12/CXCR4系统和合成卡西酮
- 批准号:
10392410 - 财政年份:2018
- 资助金额:
$ 41.76万 - 项目类别:
Psychoactive bath salts and the glutamate system
精神活性浴盐和谷氨酸系统
- 批准号:
8862040 - 财政年份:2015
- 资助金额:
$ 41.76万 - 项目类别:
Psychoactive bath salts and the glutamate system
精神活性浴盐和谷氨酸系统
- 批准号:
9321202 - 财政年份:2015
- 资助金额:
$ 41.76万 - 项目类别:
Psychoactive bath salts and the glutamate system
精神活性浴盐和谷氨酸系统
- 批准号:
9139439 - 财政年份:2015
- 资助金额:
$ 41.76万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 41.76万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 41.76万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 41.76万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 41.76万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 41.76万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 41.76万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 41.76万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 41.76万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 41.76万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 41.76万 - 项目类别:
Research Grant